Duration and type of statin use and long-term risk of type 2 diabetes among men and women with hypercholesterolaemia: findings from three prospective cohorts
Zhang Y, Li Y, Liu Y, et al.
Diabetologia. Pub. online 2 May 2025.
Leggi
Long-term effects of metformin on offspring health: a review of current evidence and future directions
Mayadunne T, Saadati S, Asmelash D, Mason T, et al.
Diabetes Obes Metab. Pub. online 6 May 2025.
Leggi
Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Su AY, Csere MM, Shan R, et al.
Diabetes Res Clin Pract. 2025:112219.
Leggi
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: an indirect treatment comparison
Hankosky ER, He X, Malik R, et al.
Diabetes Obes Metab. Pub. online 5 May 2025.
Leggi
Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: safety data from regulatory clinical trials
Parker CH, Slattery C, Brennan DJ, le Roux CW
Diabetes Obes Metab. Pub. online 6 May 2025.
Leggi
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
Sanyal AJ, Newsome PN, Kliers I, et al.
N Engl J Med. Pub. online 30 Apr 2025.
Leggi
AIFA: Monitoraggio della Spesa Farmaceutica Nazionale e Regionale Gennaio-Dicembre 2024
29/04/2025
Leggi
Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity
Sagar RC, Yates DM, Pearson SM, et al.
Diabetologia. Pub. online 30 Apr 2025.
Leggi
High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial
Aroda VR, Jørgensen NB, Kumar B, et al.
Diabetes Care. 2025:dc242425.
Leggi